Optimizing a lupus autoantibody for targeted cancer therapy

Cancer Research

Volumn 75, Issue 11, 2015, Pages 2285-2291

  Noble, Philip W ^a   Chan, Grace ^b   Young, Melissa R ^a,c   Weisbart, Richard H ^b   Hansen, James E ^a,c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; LUPUS AUTOANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; OLAPARIB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; RECOMBINANT PROTEIN;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CELL GROWTH; CELL NUCLEUS; CELL SURVIVAL; COLON CANCER; CONCENTRATION RESPONSE; DNA DAMAGE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG RESPONSE; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG CANCER; MISMATCH REPAIR; PRIORITY JOURNAL; TUMOR VOLUME; HCT116 CELL LINE; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTINUCLEAR; DNA BREAKS, DOUBLE-STRANDED; HCT116 CELLS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEOPLASMS; RECOMBINANT PROTEINS;

EID: 84939449172     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-2278     Document Type: Article

References (33)

1. Hansen JE, ChanG, Liu Y, Hegan DC, Dalal S, Dray E, et al. Targeting cancer with a lupus autoantibody. Sci Trans Med 2012;4:157ra42.
2. Weisbart RH, Stempniak M, Harris S, Zack DJ, Ferreri K. An autoantibody is modified for use as a delivery system to target the cell nucleus: therapeutic implications. J Autoimmun 1998;11:539-46.
3. Weisbart RH, Hansen JE, Chan G, Wakelin R, Chang SS, Heinze E, et al. Antibody-mediated transduction of p53 selectively kills cancer cells. Int J Oncol 2004;25:1867-73.
4. Rudnick SI, Adams GP. Affinity and avidity in antibody-based tumor targeting. Cancer Biother Radiopharm 2009;24:155-61.
5. Beckman RA, Weiner LM, Davis HM.Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007;109:170-9.
6. King DJ, Turner A, Farnsworth AP, Adair JR, Owens RJ, Pedley RB, et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994;54:6176-85.
7. Weisbart RH, Wakelin R, Chan G, Miller CW, Koeffler PH. Construction and expression of a bispecific single-chain antibody that penetratesmutant p53 colon cancer cells and binds p53. Int J Oncol 2004;25:1113-8.
8. Hansen JE, Sohn W, Kim C, Chang SS, Huang NC, Santos DG, et al. Antibody-mediated Hsp70 protein therapy. Brain Res 2006;1088:187-96.
9. Hansen JE, Tse CM, Chan G, Heinze ER, Nishimura RN, Weisbart RH. Intranuclear protein transduction through a nucleoside salvage pathway. J Biol Chem 2007;282:20790-3.
10. Zhan X, Ander BP, Liao IH, Hansen JE, Kim C, Clements D, et al. Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral ischemia in rats. Stroke 2010;41:538-43.
11. Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, et al. Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. Mol Oncol 2013;7:308-22.
12. Hucl T, Rago C, Gallmeier E, Brody JR, Gorospe M, Kern SE. A syngeneic variance library for functional annotation of human variation: application to BRCA2. Cancer Res 2008;68:5023-30.
13. McEllin B, Camacho CV, Mukherjee B, HahmB, Tomimatsu N, Bachoo RM, et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res 2010;70:5457-64.
14. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim JS, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009;1:315-22.
15. Bassi C, Ho J, Srikumar T, Dowling RJ, Gorrini C, Miller SJ, et al. Nuclear PTEN controls DNA repair and sensitivity to genotoxic stress. Science 2013;341:395-9.
16. Irwin CP, Portorreal Y, Brand C, Zhang Y, Desai P, Salinas B, et al. PARPi- FL-a fluorescent PARP1 inhibitor for glioblastoma imaging. Neoplasia 2014;16:432-40.
17. Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, et al. PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Sci Trans Med 2010; 2:53ra75.
18. Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, Ashworth A, et al. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011;8:302-6.
19. Puc J, Parsons R. PTEN loss inhibits CHK1 to cause double stranded-DNA breaks in cells. Cell Cycle 2005;4:927-9.
20. Scott AM, Wolchok JD, Old LJ. Antibody therapy of cancer. Nat Rev Cancer 2012;12:278-87.
21. Kellner C, Derer S, Valerius T, PeippM. BoostingADCCandCDCactivity by Fc engineering and evaluation of antibody effector functions. Methods 2014;65:105-13.
22. Jang SH, Wientjes MG, Lu D, Au JL. Drug delivery and transport to solid tumors. Pharm Res 2003;20:1337-50.
23. Maeda H, WuJ, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000;65:271-84.
24. Gupta A, Yang Q, Pandita RK, Hunt CR, Xiang T, Misri S, et al. Cell-cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 2009;8:2198-210.
25. Radu A, Neubauer V, Akagi T, Hanafusa H, Georgescu MM. PTEN induces cell-cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol 2003;23:6139-49.
26. Shen WH, Balajee AS, Wang J, WuH, Eng C, Pandolfi PP, et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007;128: 157-70.
27. Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-11.
28. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998;58:2720-3.
29. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356-62.
30. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
31. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-8.
32. Cancer Genome Atlas Research N. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
33. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-30.